Genomics

Dataset Information

40

Identification of selective lead compounds for treatment of high-ploidy breast cancer


ABSTRACT: Increased ploidy is common in tumors but treatments for tumors with excess chromosome sets are not available. Here, we characterize high-ploidy breast cancers and identify potential anticancer compounds selective for the high-ploidy state. Among 354 human breast cancers, 10% have mean chromosome copy number exceeding 3, and this is most common in triple negative and HER2-positive types. Women with high-ploidy breast cancers have higher risk of recurrence and death in two patient cohorts, demonstrating that it represents an important group for improved treatment. Because high-ploidy cancers are aneuploid, rather than triploid or tetraploid, we devised a two-step screen to identify selective compounds. The screen was designed to assure both external validity on diverse karyotypic backgrounds and specificity for high-ploidy cell types. This screen identified novel therapies specific to high-ploidy cells. First, we discovered 8-azaguanine, an antimetabolite that is activated by hypoxanthine phosphoribosyltransferase (HPRT), suggesting an elevated gene-dosage of HPRT in high-ploidy tumors can control sensitivity to this drug. Second, we discovered a novel compound, 2,3-Diphenylbenzo[g]quinoxaline-5,10-dione (DPBQ). DPBQ activates p53 and triggers apoptosis in a polyploid-specific manner, but does not inhibit topoisomerase or bind DNA. Mechanistic analysis demonstrates that DPBQ elicits a hypoxia gene signature and its effect is replicated, in part, by enhancing oxidative stress. Structure-function analysis defines the core benzo[g]quinoxaline-5,10 dione as being necessary for the polyploid-specific effects of DPBQ. We conclude that polyploid breast cancers represent a high-risk subgroup and that DPBQ provides a functional core to develop polyploid-selective therapy. Overall design: Expression data from MCF7s +/- DPBQ We used microarrays to evaluate the effect of DPBQ on gene expression MCF7 cells were treated with or without DPBQ for 6 hours for RNA extraction and hybridization on Affymetrix microarrays

INSTRUMENT(S): [HG-U133A_2] Affymetrix Human Genome U133A 2.0 Array

ORGANISM(S): Homo Sapiens

SUBMITTER: Mark Burkard 

PROVIDER: GSE73710 | GEO | 2015-10-03

SECONDARY ACCESSION(S): PRJNA297725

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
GSE73710_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 2 of 2
altmetric image

Publications


Increased ploidy is common in tumors but treatments for tumors with excess chromosome sets are not available. Here, we characterize high-ploidy breast cancers and identify potential anticancer compounds selective for the high-ploidy state. Among 354 human breast cancers, 10% have mean chromosome copy number exceeding 3, and this is most common in triple-negative and HER2-positive types. Women with high-ploidy breast cancers have higher risk of recurrence and death in two patient cohorts, demonst  ...[more]

Similar Datasets

| S-EPMC4707107 | BioStudies
| S-EPMC8282749 | BioStudies
| S-EPMC7843634 | BioStudies
| PRJNA297725 | ENA
| S-EPMC5671579 | BioStudies
2019-01-01 | GSE108645 | GEO
| S-EPMC7726793 | BioStudies
| S-SCDT-EMBOR-2020-50893-T | BioStudies
| S-EPMC4928784 | BioStudies
| S-EPMC4343275 | BioStudies